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Abstract 
Purpose: To report a case of bilateral acute angle-closure glaucoma after oral 
administration of cabergoline for the treatment of galactorrhea.  
Methods: A diagnosis of secondary drug-induced angle-closure glaucoma was made in a 
patient with elevated intraocular pressure (IOP) and myopic refractive shift, which was 
confirmed by ultrasound biomicroscopy (UBM) of the ciliary body and anterior segment, 
sonography, and optical coherence tomography. The treatment included the 
discontinuation of the culprit drug and the administration of topical anti-glaucoma 
drops. The treatment course was followed with serial measurements of the IOP and 
refraction, and with performing UBM.  
Results: Five hours after he received a single 0.5-mg oral cabergoline tablet, the patient 
suffered from acute secondary angle-closure glaucoma and myopic refractive error. UBM 
demonstrated both effusion of the ciliary body and an anterior rotation of the iris-ciliary 
body. IOP was reduced 8 h after cessation of the causative agent and administration of 
anti-glaucoma drops. Refractive errors returned to normal levels after 8 days.  
Conclusion: Secondary acute angle-closure glaucoma has been reported to occur after 
the administration of some drugs. In this report, an attempt has been made to describe 
this adverse reaction after oral cabergoline intake. 
 
Introduction 
Drug-induced glaucoma is a form of secondary glaucoma. Several types of drugs, such 
as adrenergic agonists, cholinergics, anti-cholinergics, sulfa-based drugs (e.g. topiramate), 
selective serotonin reuptake inhibitors, tricyclic and tetracyclic anti-depressants,  
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anticoagulants, and antihistamines, have been reported to induce secondary acute angle-
closure glaucoma [1–12]. 
Cabergoline (brand names Dostinex and Cabaser), an ergot derivative, is a potent 
dopamine D2 receptor agonist. The drug is prescribed in Parkinson’s disease, prolactin-
producing pituitary gland tumors, ablactation and dysfunctions associated with 
hyperprolactinemia. It stimulates dopamine receptors in lactophilic hypothalamic cells to 
suppress prolactin secretion in the pituitary gland [13, 14]. 
To the best of our knowledge, no cabergoline-induced glaucoma report has been 
published in the literature yet. 
Case Report 
One year after weaning her child, a 22-year-old female developed galactorrhea. She was prescribed 
0.5-mg oral cabergoline tablets by her gynecologist (one tablet per week); however, she did not receive 
any other medication. 
Five hours after ingestion of the first single dose of cabergoline, the patient was referred to our 
hospital suffering from bilateral painful red eyes, blurred vision, headache, nausea, and vomiting. 
Initially, the symptoms occured in her left eye, but, consequently, they also developed in her right eye. 
The patient had no past medical and familial history of glaucoma, other ophthalmologic diseases or 
refractive errors. 
Ocular examination revealed  an uncorrected visual acuity of 20/200 in the right and 20/400 in the 
left eye, normal external ocular motion in both eyes, 5-mm pupils in both eyes that were nonreactive to 
light, a conjunctival hyperemia and a perilimbal injection. In addition, the examination showed a 
microcystic corneal edema, a shallow anterior chamber, a closed angle in gonioscopy as well as a clear 
lens. The fundus demonstrated normal disc and vessels, a normal foveal light reflex as well as some 
perifoveal retinal wrinkling secondary to choroidal thickening. The intraocular pressure (IOP), 
measured using Goldmann applanation tonometry, was 40 mm Hg in the right and 42 mm Hg in the 
left eye. Refractive errors were –7.75 dpt sph and –1.00 × 94° cyl in the right eye, and –9.00 dpt sph and 
–0.50 × 56° cyl in the left eye. 
 
Ultrsonagraphy with a 10-MHz probe revealed choroidal thickening in both eyes. Ultrasound 
biomicroscopy with a 40-MHz probe showed ciliochoroidal thickening, effusion underneath the ciliary 
body, narrowing of the angle and anterior rotation of the iris-ciliary body in both eyes (fig. 1). 
Measured axial lengths were 23.22 and 23.24 mm in the right and left eye, respectively. The anterior 
chamber depth was 1.33 mm in the right and 1.34 in left eye. Results of a posterior pole optical 
coherence tomography were normal in both eyes. 
Treatment of the patient was immediately started with the discontinuation of cabergoline as the 
suspicious causal drug. The elevated IOP was treated with topical timolol maleate 0.5% every 12 h, 
brimonidine tartrate 0.1% every 8 h, and latanoprost 0.005% every 24 h. 
Glaucoma was controlled 8 h after medical treatment, IOP was reduced to 25 mm Hg in both eyes, 
conjunctival hyperemia was reduced, and ocular pain was alleviated; however, the patient still had a 
myopic shift in refraction. Finally, by 8 days after cessation of cabergoline, the refraction returned to 
normal levels. 
Discussion 
Cabergoline is absorbed from the gastrointestinal tract within 0.5 to 4 h, with an 
average elimination half-life of 80 h. Seventy-nine percent of the patients taking this drug  
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report at least one side effect. These side effects are chiefly mild or moderate, including 
nausea, constipation, dry mouth, gastric irritation, dyspepsia, sleep disturbances, vertigo, 
depression, dyskinesia, hallucinations, systemic hypotension, peripheral edema, 
arrhythmia, and angina pectoris [15–20]. We were not able to find any previous report of 
glaucoma symptoms and signs in the literature. 
Acute drug-induced bilateral glaucoma is a relatively uncommon but serious adverse 
reaction which, if not recognized in a timely manner, may result in severe morbidity and 
even permanent visual damage. Its treatment differs from that of primary acute angle-
closure glaucoma, i.e. it is necessary to discontinue the drug for controlling glaucoma  
[1–5]. 
 
 
 
 
 
 
Fig. 1. Choroidal effusion and ciliochoroidal anterior displacement in UBM. 
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